常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.69/-0.39
|
|
企業價值
1.51B
|
| 資產負債 |
|
每股賬面淨值
0.40
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
314.00K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 02:41 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. |

4 
